OBJECTIVE: To determine the rate of decline of CD4 T lymphocytes among HIV-1-infected individuals. DESIGN AND SETTING: A prospective open cohort study of workers in three hotels in Dar es Salaam. METHODS: The workers were seen yearly during the study. CD4 T lymphocyte counts were determined using flow cytometry. The CD4 T-lymphocyte slopes were determined using a linear regression model. RESULTS: During the 9-year study period 682 subjects were selected for lymphocyte subset determinations. Of these, 94 HIV-1-seroprevalent (72%), 77 HIV-1-seroincident (67%) and 325 seronegative (75%) individuals had three or more CD4 T-cell determinations, and were used for calculations of CD4 cell slopes with a mean follow-up period of 71.4, 52.9 and 86.0 months, respectively. The median yearly decline of the CD4 T-lymphocyte counts and percentages among seroprevalent individuals was -21.5 cells/microl and -1.3%; among the seroincident individuals the median decline was -22.0 cells/microl and -1.5%. In seroincident individuals the mean duration to a CD4 T-lymphocyte level corresponding to a definition of AIDS was 13.3 years or 11.8 years for CD4 cell counts or percentages, respectively. HIV-1-seropositive subjects who died had significantly steeper CD4 cell slopes than those who survived. CONCLUSION: The rates of CD4 T-lymphocyte decline in HIV-1-infected individuals in our population are similar to those reported in Europe and north America.
OBJECTIVE: To determine the rate of decline of CD4 T lymphocytes among HIV-1-infected individuals. DESIGN AND SETTING: A prospective open cohort study of workers in three hotels in Dar es Salaam. METHODS: The workers were seen yearly during the study. CD4 T lymphocyte counts were determined using flow cytometry. The CD4 T-lymphocyte slopes were determined using a linear regression model. RESULTS: During the 9-year study period 682 subjects were selected for lymphocyte subset determinations. Of these, 94 HIV-1-seroprevalent (72%), 77 HIV-1-seroincident (67%) and 325 seronegative (75%) individuals had three or more CD4 T-cell determinations, and were used for calculations of CD4 cell slopes with a mean follow-up period of 71.4, 52.9 and 86.0 months, respectively. The median yearly decline of the CD4 T-lymphocyte counts and percentages among seroprevalent individuals was -21.5 cells/microl and -1.3%; among the seroincident individuals the median decline was -22.0 cells/microl and -1.5%. In seroincident individuals the mean duration to a CD4 T-lymphocyte level corresponding to a definition of AIDS was 13.3 years or 11.8 years for CD4 cell counts or percentages, respectively. HIV-1-seropositive subjects who died had significantly steeper CD4 cell slopes than those who survived. CONCLUSION: The rates of CD4 T-lymphocyte decline in HIV-1-infected individuals in our population are similar to those reported in Europe and north America.
Authors: Richard C Waters; Jan Ostermann; Travis D Reeves; Max F Masnick; Nathan M Thielman; John A Bartlett; John A Crump Journal: J Acquir Immune Defic Syndr Date: 2011-04-15 Impact factor: 3.731
Authors: Noah Kiwanuka; Merlin Robb; Oliver Laeyendecker; Godfrey Kigozi; Fred Wabwire-Mangen; Fredrick E Makumbi; Fred Nalugoda; Joseph Kagaayi; Michael Eller; Leigh Anne Eller; David Serwadda; Nelson K Sewankambo; Steven J Reynolds; Thomas C Quinn; Ronald H Gray; Maria J Wawer; Christopher C Whalen Journal: J Acquir Immune Defic Syndr Date: 2010-06 Impact factor: 3.731
Authors: Judd L Walson; Phelgona A Otieno; Margaret Mbuchi; Barbra A Richardson; Barbara Lohman-Payne; Steve Wanyee Macharia; Julie Overbaugh; James Berkley; Eduard J Sanders; Michael H Chung; Grace C John-Stewart Journal: AIDS Date: 2008-08-20 Impact factor: 4.177
Authors: Paul Kelly; Max Katubulushi; Jim Todd; Rose Banda; Vera Yambayamba; Mildred Fwoloshi; Isaac Zulu; Emmanuel Kafwembe; Felistah Yavwa; Ian R Sanderson; Andrew Tomkins Journal: Am J Clin Nutr Date: 2008-10 Impact factor: 7.045
Authors: Eline L Korenromp; Brian G Williams; Sake J de Vlas; Eleanor Gouws; Charles F Gilks; Peter D Ghys; Bernard L Nahlen Journal: Emerg Infect Dis Date: 2005-09 Impact factor: 6.883